About Us

Contact us
Community Advisory Board
Readers Rep
Careers
Events
Historical Archives
Recent Quotes
My Watchlist
Indicators
Local Stocks
San Diego Stocks
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

RAPT Therapeutics, Inc. - Common Stock (NQ: RAPT )

1.210 +0.100 (+9.01%)
Streaming Delayed Price Updated: 4:00 PM EST, Feb 5, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 487,180
Open 1.130
Bid (Size) 1.150 (3)
Ask (Size) 1.230 (2)
Prev. Close 1.110
Today's Range 1.120 - 1.210
52wk Range 0.7893 - 27.35
Shares Outstanding 34,358,152
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
RAPT Therapeutics to Present at the 43rd Annual J.P. Morgan Healthcare Conference
From RAPT Therapeutics, Inc.
Via GlobeNewswire
RAPT Therapeutics Names Lori Lyons-Williams Chair of the Company’s Board of Directors
From RAPT Therapeutics, Inc.
Via GlobeNewswire

Performance

YTD
-25.77%
-25.77%
1 Month
-29.65%
-29.65%
3 Month
-55.51%
-55.51%
6 Month
-49.79%
-49.79%
1 Year
-95.31%
-95.31%

More News

Read More
Futures Slide As Bond Yields Jump To 6 Month High
Via Talk Markets
Topics Bonds Commodities Cryptocurrencies
Exposures Debt Markets
12 Health Care Stocks Moving In Thursday's Pre-Market Session
Via Benzinga
This Progressive Analyst Turns Bullish; Here Are Top 3 Upgrades For Thursday
Via Benzinga
12 Health Care Stocks Moving In Monday's Pre-Market Session
Via Benzinga
Why RAPT Therapeutics Stock Gained Over 100% On Monday?
Via Benzinga
US Stocks Mixed, Dow Tumbles 150 Points
Via Benzinga
Topics Stocks
Exposures US Equities
RAPT Therapeutics Announces $150 Million Private Placement
From RAPT Therapeutics, Inc.
Via GlobeNewswire
RAPT Therapeutics and Shanghai Jemincare Pharmaceutical Announce Exclusive License Agreement for Novel Long-Acting anti-IgE Antibody
From RAPT Therapeutics, Inc.
Via GlobeNewswire
RAPT Therapeutics Reports Third Quarter 2024 Financial Results
From RAPT Therapeutics, Inc.
Via GlobeNewswire
12 Health Care Stocks Moving In Monday's Pre-Market Session
Via Benzinga
Crude Oil Down 3%; Aramark Posts Upbeat Earnings
Via Benzinga
Exposures Fossil Fuels
Nasdaq Moves Lower; Canaan Shares Surge
Via Benzinga
Rapt Therapeutics Stock Plummets, Terminates Asthma Trial Due To Patient's Liver Injury
Via Benzinga
Exposures Product Safety
Dow Jumps Over 400 Points; Monday.com Shares Fall After Q3 Results
Via Benzinga
Topics Stocks
Exposures US Equities
Based on Recent FDA Feedback RAPT Therapeutics Stops Zelnecirnon Program Following Clinical Hold Due to Single SAE of Severe Liver Injury
From RAPT Therapeutics, Inc.
Via GlobeNewswire
12 Health Care Stocks Moving In Wednesday's Intraday Session
Via Benzinga
10 Health Care Stocks Moving In Monday's Pre-Market Session
Via Benzinga
12 Health Care Stocks Moving In Wednesday's Intraday Session
Via Benzinga
RAPT Stock Earnings: RAPT Therapeutics Beats EPS for Q2 2024
Via InvestorPlace
RAPT Therapeutics Reports Second Quarter 2024 Financial Results
From RAPT Therapeutics, Inc.
Via GlobeNewswire
12 Health Care Stocks Moving In Monday's After-Market Session
Via Benzinga
Top 5 Health Care Stocks Which Could Rescue Your Portfolio This Month
Via Benzinga
INVESTIGATION ALERT: The Schall Law Firm Announces it is Investigating Claims Against RAPT Therapeutics, Inc. and Encourages Investors to Contact the Firm
From Schall Law
Via GlobeNewswire
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.